U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N4O5
Molecular Weight 334.3278
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITOMYCIN

SMILES

CC1=C(C(=O)C2=C(C1=O)N3C[C@@]4([H])[C@@]([H])([C@@]3([C@]2([H])COC(=N)O)OC)N4)N

InChI

InChIKey=NWIBSHFKIJFRCO-WUDYKRTCSA-N
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00305 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf https://en.wikipedia.org/wiki/Mitomycins

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.

CNS Activity

Curator's Comment:: An intact blood-brain barrier in the brain and spinal cord prevented mitomycin C from producing adverse effects in the central nervous system. Within the spinal canal, spinal nerves and the spinal cord are connected by the ventral and dorsal roots. The spinal nerve is part of the peripheral nervous system and is not protected from mitomycin C by the blood-brain barrier

Originator

Curator's Comment:: In 1956, Hata isolated mitomycin-A & mitomycin-B from Steptomyces caespitosus that had antibiotic & antitumour activities. Dr Hata along with Dr Shigetoshi Wakagi from Kyowa Hakko Kogyo company later reported the isolation of mitomycin-C from the same fermentation broth at a higher pH and that this compound had much higher antitumour activity. After the success of intravesical therapy using Thiotepa in 1961 by Jones and Swinney, Dr Shida and his colleagues reported in a Japanese journal the use of mitomycin C.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
MITOSOL

Approved Use

is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery

Launch Date

1.34118716E12
Palliative
MITOMYCIN

Approved Use

Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.

Launch Date

1.34118716E12
Palliative
MITOMYCIN

Approved Use

Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.

Launch Date

1.34118716E12
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
630 μg × h/L
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
773 μg × h/L
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50 min
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
54 min
10 mg/m² single, intravenous
dose: 10 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
76%
MITOMYCIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.2 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 3.2 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 3.2 mg/m2, 1 times / day
Co-administed with::
5-FU, i.v(600 mg/m2/day)
Sources: Page: p.816
unhealthy, 36.2 - 68.0
n = 6
Health Status: unhealthy
Condition: Head and neck cancer
Age Group: 36.2 - 68.0
Sex: M+F
Population Size: 6
Sources: Page: p.816
4 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / day
Co-administed with::
5-FU, i.v(600 mg/m2/day)
Sources: Page: p.816
unhealthy, 36.2 - 68.0
n = 6
Health Status: unhealthy
Condition: Head and neck cancer
Age Group: 36.2 - 68.0
Sex: M+F
Population Size: 6
Sources: Page: p.816
DLT: Dysphagia, Mucositis...
Dose limiting toxicities:
Dysphagia (grade 3, 16.7%)
Mucositis (grade 3, 33.3%)
Sources: Page: p.816
6 mg/m2 1 times / 4 weeks multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / 4 weeks
Co-administed with::
docetaxel , i.v(60 mg/m2)
cisplatin, i.v(80 mg/m2)
Sources: Page: p.548
unhealthy, 53-71
n = 3
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: 53-71
Sex: M+F
Population Size: 3
Sources: Page: p.548
DLT: Febrile neutropenia, Hyponatremia...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 33.3%)
Hyponatremia (grade 3, 33.3%)
Sources: Page: p.548
15 mg/m2 single, intravenous
Recommended
Dose: 15 mg/m2
Route: intravenous
Route: single
Dose: 15 mg/m2
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas
Sources: Page: p.1
Disc. AE: Bone marrow depression, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Thrombocytopenia
Leukopenia
Hemolytic uremic syndrome
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dysphagia grade 3, 16.7%
DLT
4 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / day
Co-administed with::
5-FU, i.v(600 mg/m2/day)
Sources: Page: p.816
unhealthy, 36.2 - 68.0
n = 6
Health Status: unhealthy
Condition: Head and neck cancer
Age Group: 36.2 - 68.0
Sex: M+F
Population Size: 6
Sources: Page: p.816
Mucositis grade 3, 33.3%
DLT
4 mg/m2 1 times / day multiple, intravenous
Studied dose
Dose: 4 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / day
Co-administed with::
5-FU, i.v(600 mg/m2/day)
Sources: Page: p.816
unhealthy, 36.2 - 68.0
n = 6
Health Status: unhealthy
Condition: Head and neck cancer
Age Group: 36.2 - 68.0
Sex: M+F
Population Size: 6
Sources: Page: p.816
Hyponatremia grade 3, 33.3%
DLT
6 mg/m2 1 times / 4 weeks multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / 4 weeks
Co-administed with::
docetaxel , i.v(60 mg/m2)
cisplatin, i.v(80 mg/m2)
Sources: Page: p.548
unhealthy, 53-71
n = 3
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: 53-71
Sex: M+F
Population Size: 3
Sources: Page: p.548
Febrile neutropenia grade 4, 33.3%
DLT
6 mg/m2 1 times / 4 weeks multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / 4 weeks
Co-administed with::
docetaxel , i.v(60 mg/m2)
cisplatin, i.v(80 mg/m2)
Sources: Page: p.548
unhealthy, 53-71
n = 3
Health Status: unhealthy
Condition: Non-small cell lung cancer
Age Group: 53-71
Sex: M+F
Population Size: 3
Sources: Page: p.548
Bone marrow depression Disc. AE
15 mg/m2 single, intravenous
Recommended
Dose: 15 mg/m2
Route: intravenous
Route: single
Dose: 15 mg/m2
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas
Sources: Page: p.1
Hemolytic uremic syndrome Disc. AE
15 mg/m2 single, intravenous
Recommended
Dose: 15 mg/m2
Route: intravenous
Route: single
Dose: 15 mg/m2
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas
Sources: Page: p.1
Leukopenia Disc. AE
15 mg/m2 single, intravenous
Recommended
Dose: 15 mg/m2
Route: intravenous
Route: single
Dose: 15 mg/m2
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas
Sources: Page: p.1
Thrombocytopenia Disc. AE
15 mg/m2 single, intravenous
Recommended
Dose: 15 mg/m2
Route: intravenous
Route: single
Dose: 15 mg/m2
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas
Sources: Page: p.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
1976 Mar
[Microangiopathic hemolytic anemia associated with mitomycin-C treatment].
1991 Dec
Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.
1992
Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C.
1992 Aug 15
Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.
1992 Jul
Serious complications of topical mitomycin-C after pterygium surgery.
1992 Nov
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
1992 Sep
Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma.
2002 May
Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer.
2003
Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
2003 Apr
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
2003 Jan
Anticancer drug resistance of HeLa cells transfected with rat glutathione S-transferase pi gene.
2003 Jun
Mitomycin C-induced renal insufficiency: a case report.
2003 Jun
[Mitomycin-induced hemolytic-uremic syndrome].
2003 Jun 20
NAD(P)H: quinone oxidoreductase 1 expression in kidney podocytes.
2003 Mar
Apoptosis of bladder cancer cells induced by short-term and low-dose Mitomycin-C: potential molecular mechanism and clinical implication.
2003 Mar
Genomic and proteomic profiling of responses to toxic metals in human lung cells.
2003 May
Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.
2004 Jan
Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice.
2004 Jun
Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic and remetastatic cell lines?
2004 Mar-Apr
Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.
2004 May
Effect of in vitro and in vivo treatment with mitomycin C on activities of CYP2D1/2, CYP2C11, and CYP1A2 in rat liver.
2004 Nov
The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome.
2004 Oct
Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes.
2004 Sep 10
In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells.
2005
Drug-induced thrombotic microangiopathy.
2005 Dec
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
2005 Feb
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
2005 Feb
Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway.
2005 Jul 15
Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells.
2005 Jul 29
Otologic effects of topical mitomycin C: phase I-evaluation of ototoxicity.
2005 Mar
Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
2005 Mar 28
Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease.
2005 Oct
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
2006 Aug 1
Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function.
2006 Aug 15
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.
2006 Feb
Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
2006 Oct
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
2007 Dec 3
Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma.
2007 Jun
Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways.
2007 Jun 15
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
2007 May
Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
2007 May-Jun
Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes.
2008 Aug 15
[Expression of survivin mRNA and protein in mitomycin-treated hepatoma carcinoma Hepa1-6 cells].
2008 Feb
Mitomycin C induces multidrug resistance in glaucoma surgery.
2008 Feb
Hemolytic uremic syndrome.
2008 Jul
Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas.
2008 Jun 30
Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin.
2008 Oct
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.
2008 Sep 2
The mouse lymphoma assay detects recombination, deletion, and aneuploidy.
2009 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Is intended for topical application to the surgical site of glaucoma filtration surgery. It is not intended for intraocular administration. If intraocular administration occurs, cell death leading to corneal infarction, retinal infarction, and ciliary body atrophy may result. One more route of administration: Mitomycin should be given intravenously only, using care to avoid extravasation of the compound. If extravasation occurs, cellulitis, ulceration, and slough may result. Each vial contains mitomycin 20 mg and mannitol 40 mg or mitomycin 40 mg and mannitol 80 mg. To administer, add Sterile Water for Injection, 40 mL or 80 mL respectively. Shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until solution is obtained | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1300e9-ca6e-4713-b41a-bb913aed3287
Sponges provided within the Mitosol ® Kit should be fully saturated with the entire reconstituted contents. A treatment area approximating 10 mm x 6 mm +/- 2 mm should be treated with the Mitosol®.
Route of Administration: Topical
In Vitro Use Guide
The molecular mechanism of differentiation interruption by mitomycin C in the Non-small-cell lung cancer (NSCLC) line A549 was investigated. High dosage of mitomycin C (300 µM) could significantly inhibit cell proliferation (P < 0.05) by 48.39 ± 3.32% (P < 0.05), under which cell shrinkage and disruption were observed
Name Type Language
MITOMYCIN
EP   HSDB   INN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
MITOMYCIN C [IARC]
Common Name English
MITOMYCIN [USAN]
Common Name English
AMETYCINE
Brand Name English
MITOMYCIN C [JAN]
Common Name English
UGN-101
Code English
JELMYTO
Brand Name English
MITOMYCIN [HSDB]
Common Name English
MITOMYCIN C
MI  
Common Name English
MITOMYCIN [VANDF]
Common Name English
MITOMYCIN [USP MONOGRAPH]
Common Name English
MITOMYCIN C [MI]
Common Name English
MITOMYCIN [INN]
Common Name English
MUAMYCIN
Brand Name English
MUTAMYCIN
Brand Name English
MITOCIN-C
Brand Name English
6-AMINO-1,1A,2,8,8A,8B-HEXAHYDRO-8-(HYDROXYMETHYL)-8A-METHOXY-5-METHYLAZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE CARBAMATE (ESTER)
Common Name English
UGN-102
Code English
MITOMYCIN [WHO-DD]
Common Name English
MITOSOL
Brand Name English
MITOMYCIN [MART.]
Common Name English
MYTOZYTREX
Brand Name English
AZIRINO(2',3':3,4)PYRROLO(1,2-A)INDOLE-4,7-DIONE, 6-AMINO-8-(((AMINOCARBONYL)OXY)METHYL)-1,1A,2,8,8A,8B-HEXAHYDRO-8A-METHOXY-5-METHYL-, (1AS-(1A.ALPHA.,8.BETA.,8A.ALPHA.,8B.ALPHA.))-
Common Name English
MITOMYCIN [ORANGE BOOK]
Common Name English
MITOMYCIN [USP-RS]
Common Name English
MITOMYCIN [EP MONOGRAPH]
Common Name English
MITOMYCIN-C
Common Name English
NSC-26980
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 312510
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
FDA ORPHAN DRUG 251407
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
NCI_THESAURUS C663
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
NDF-RT N0000000236
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
NDF-RT N0000175558
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
FDA ORPHAN DRUG 305610
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
FDA ORPHAN DRUG 445114
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
WHO-VATC QL01DC03
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
LIVERTOX 646
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
FDA ORPHAN DRUG 73493
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
IARC Mitomycin C
WHO-ATC L01DC03
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
Code System Code Type Description
FDA UNII
50SG953SK6
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
INN
3043
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
MERCK INDEX
M7570
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY Merck Index
HSDB
3239
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
CAS
50-07-7
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
RXCUI
632
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY RxNorm
IUPHAR
7089
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-008-6
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
USP_CATALOG
1444707
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB00305
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL105
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
EVMPD
SUB09006MIG
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
EPA CompTox
50-07-7
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
MESH
D016685
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
PUBCHEM
5746
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
NCI_THESAURUS
C1820
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
WIKIPEDIA
MITOMYCIN
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY
DRUG CENTRAL
1819
Created by admin on Fri Jun 25 21:05:57 UTC 2021 , Edited by admin on Fri Jun 25 21:05:57 UTC 2021
PRIMARY